Connect Biopharma Holdings Income Statement (2023-2025) | CNTB

Income Statement Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 1.22M0.70M0.05M0.02M
Operating items
Research & Development 8.66M5.35M9.01M6.24M6.63M8.77M11.11M
Selling, General & Administrative 3.97M5.12M6.06M4.08M4.81M4.70M6.58M
Operating Expenses 12.63M10.47M15.06M10.32M11.45M13.47M17.69M
Operating Income -12.63M13.65M-13.85M-9.62M-11.45M-13.42M-17.68M
EBIT -12.63M13.65M-13.85M-9.62M-11.45M-13.42M-17.68M
Non-operating items
Interest & Investment Income 1.25M1.22M1.14M0.85M0.72M0.62M0.55M
Other Non Operating Income 2.72M0.01M-0.11M-0.03M0.51M-0.04M-0.01M
Non Operating Income 3.97M1.23M1.03M0.82M1.23M0.58M0.54M
Net income details
EBT -8.66M14.88M-12.82M-8.80M-10.22M-12.84M-17.14M
Tax Provisions 0.03M0.03M0.06M0.11M0.05M0.06M0.06M
Profit After Tax -8.69M14.85M-12.88M-8.91M-10.27M-12.90M-17.20M
Income from Continuing Operations -8.69M14.85M-12.88M-8.91M-10.27M-12.90M-17.20M
Consolidated Net Income -8.69M14.85M-12.88M-8.91M-10.27M-12.90M-17.20M
Income towards Parent Company -8.69M14.85M-12.88M-8.91M-10.27M-12.90M-17.20M
Net Income towards Common Stockholders -8.69M14.85M-12.88M-8.91M-10.27M-12.90M-17.20M
Additional items
EPS (Basic) -0.160.27-0.23-0.16-0.19-0.23-0.31
EPS (Weighted Average and Diluted) -0.160.27-0.23-0.16-0.19-0.23-0.31
Shares Outstanding (Weighted Average) 55.07M55.10M55.19M55.25M55.21M55.35M55.50M55.72M
Shares Outstanding (Diluted Average) 55.07M55.10M55.71M55.25M55.21M55.35M55.50M55.72M
EBITDA -8.92M14.93M-12.31M-9.99M-10.21M-12.67M-17.10M
Tax Rate -0.35%0.20%-0.44%-1.20%-0.53%-0.43%-0.36%